Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis
Melanoma patients with pre-existing AIDs are at significant risk of flare with ICI use. These patients had an increased risk of irAEs of any grade. Although there was a trend towards increased risk of severe irAEs, this was not statistically significant. irAEs did not result in treatment-related deaths, and there were no differences in treatment response. Risks should be discussed, coupled with close monitoring.
Authors
- Joseph Descallar (ORCID: https://orcid.org/0000-0002-6919-4865)
- S. Haider (ORCID: https://orcid.org/0000-0001-6048-2521)
- Karuna Keat
- Martin Hong (ORCID: https://orcid.org/0000-0002-2327-4261)
- Tara L. Roberts (ORCID: https://orcid.org/0000-0001-9266-0943)
- Wei Chua (ORCID: https://orcid.org/0000-0002-2021-3586)
- B. Balakrishnar (ORCID: https://orcid.org/0009-0001-1622-4805)
Institutions
- Camden and Campbelltown Hospitals (AU)
- Liverpool Hospital (AU)
- North West Regional Hospital (AU)
- St Vincent's Clinic (AU)
- Ingham Institute (AU)
- South Western Sydney Local Health District (AU)
- Western Sydney University (AU)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1016/j.iotech.2025.101559
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00